Literature DB >> 21904384

The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations.

E Tiacci, A Spanhol-Rosseto, M P Martelli, L Pasqualucci, H Quentmeier, V Grossmann, H G Drexler, B Falini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21904384     DOI： 10.1038/leu.2011.238

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Human AP-endonuclease (Ape1) activity on telomeric G4 structures is modulated by acetylatable lysine residues in the N-terminal sequence.

Authors:  Silvia Burra; Daniela Marasco; Matilde Clarissa Malfatti; Giulia Antoniali; Antonella Virgilio; Veronica Esposito; Bruce Demple; Aldo Galeone; Gianluca Tell
Journal:  DNA Repair (Amst)       Date:  2018-11-22

2.  HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

Authors:  Glenda J Dickson; Fabio G Liberante; Laura M Kettyle; Kathleen A O'Hagan; Damian P J Finnegan; Lars Bullinger; Dirk Geerts; Mary Frances McMullin; Terry R J Lappin; Ken I Mills; Alexander Thompson
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

3.  Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent.

Authors:  Narisa Chan; Tit Meng Lim
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

4.  BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.

Authors:  Helen Jayne Susan Stewart; Gillian Abigail Horne; Sarah Bastow; Timothy James Telfer Chevassut
Journal:  Cancer Med       Date:  2013-10-31       Impact factor: 4.452

5.  High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.

Authors:  Ban Xiong Tan; Kian Hoe Khoo; Tit Meng Lim; David Philip Lane
Journal:  Oncotarget       Date:  2014-02-28

6.  DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.

Authors:  Kirstin Lund; John J Cole; Nathan D VanderKraats; Tony McBryan; Nikolay A Pchelintsev; William Clark; Mhairi Copland; John R Edwards; Peter D Adams
Journal:  Genome Biol       Date:  2014-08-30       Impact factor: 13.583

7.  DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.

Authors:  Junji Koya; Keisuke Kataoka; Tomohiko Sato; Masashige Bando; Yuki Kato; Takako Tsuruta-Kishino; Hiroshi Kobayashi; Kensuke Narukawa; Hiroyuki Miyoshi; Katsuhiko Shirahige; Mineo Kurokawa
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

8.  DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1.

Authors:  Jie Xu; Wu Zhang; Xiao-Jing Yan; Xue-Qiu Lin; Wei Li; Jian-Qing Mi; Jun-Min Li; Jiang Zhu; Zhu Chen; Sai-Juan Chen
Journal:  J Hematol Oncol       Date:  2016-10-10       Impact factor: 17.388

9.  Destabilisation, aggregation, toxicity and cytosolic mislocalisation of nucleophosmin regions associated with acute myeloid leukemia.

Authors:  Pasqualina Liana Scognamiglio; Concetta Di Natale; Marilisa Leone; Roberta Cascella; Cristina Cecchi; Lisa Lirussi; Giulia Antoniali; Domenico Riccardi; Giancarlo Morelli; Gianluca Tell; Fabrizio Chiti; Daniela Marasco
Journal:  Oncotarget       Date:  2016-09-13

10.  5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.

Authors:  Jae-Sook Ahn; Hyeoung-Joon Kim; Yeo-Kyeoung Kim; Seung-Shin Lee; Seo-Yeon Ahn; Sung-Hoon Jung; Deok-Hwan Yang; Je-Jung Lee; Hee Jeong Park; Seung Hyun Choi; Chul Won Jung; Jun-Ho Jang; Hee Je Kim; Joon Ho Moon; Sang Kyun Sohn; Jong-Ho Won; Sung-Hyun Kim; Szardenings Michael; Mark D Minden; Dennis Dong Hwan Kim
Journal:  Oncotarget       Date:  2017-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.